Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase

Background A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma. Objectives We sought to assess the efficacy of omalizumab treatment in patients with CU with IgE autoantibodies against TPO. Methods In this multicenter, randomized, double-blind, placebo-controlled study patients with CU (male/female, 18-70 years of age) with IgE autoantibodies against TPO who had pers…

Blindness, tetraspasticity, and other signs of irreversible brain damage in hereditary angioedema

Recommendations for photopatch testing by the Photopatch Test Working Group of the German Contact Dermatitis Research Group (DKG).